JW Lifescience Corporation (KRX:234080)
South Korea · Delayed Price · Currency is KRW 13,620
+140 (1.04%)
Feb 20, 2026, 3:30 PM KST
JW Lifescience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 47,589 | 43,988 | 28,144 | 14,961 | 12,914 | 17,300 |
Depreciation & Amortization | 17,383 | 15,737 | 15,531 | 14,956 | 13,245 | 12,246 |
Loss (Gain) From Sale of Assets | -40.19 | 31.79 | 205.81 | 95.87 | 362.94 | 4.14 |
Asset Writedown & Restructuring Costs | - | - | - | - | -85 | 46.75 |
Loss (Gain) From Sale of Investments | - | - | 43.5 | - | - | - |
Loss (Gain) on Equity Investments | -12,083 | -10,392 | -6,532 | 4,921 | 4,780 | 7,129 |
Other Operating Activities | -9,456 | -1,638 | 1,399 | 1,575 | 2,607 | 11,622 |
Change in Accounts Receivable | 4,916 | 17,232 | -2,079 | -21,103 | 2,576 | -828.49 |
Change in Inventory | -4,203 | -5,834 | -1,285 | -1,057 | -4,517 | -999.73 |
Change in Accounts Payable | -2,193 | -4,794 | 3,540 | 2,730 | 1,781 | -554.22 |
Change in Other Net Operating Assets | -783.99 | -3,640 | -1,392 | -2,950 | -3,498 | 788.97 |
Operating Cash Flow | 41,124 | 50,690 | 37,574 | 14,129 | 30,165 | 46,755 |
Operating Cash Flow Growth | -26.76% | 34.91% | 165.94% | -53.16% | -35.48% | 92.60% |
Capital Expenditures | -13,594 | -10,307 | -8,153 | -8,079 | -18,976 | -15,931 |
Sale of Property, Plant & Equipment | 110.56 | 4.9 | 3.7 | 2 | 1.71 | 9.49 |
Cash Acquisitions | -49,437 | -49,437 | - | - | - | - |
Sale (Purchase) of Intangibles | 130.32 | 61.87 | -113.8 | -214.05 | -259.87 | -307.25 |
Investment in Securities | 5,000 | 6,516 | 17,036 | -24,755 | -655.91 | -19,700 |
Other Investing Activities | -15,378 | -14,873 | -736.19 | -0.26 | 184.97 | 67.62 |
Investing Cash Flow | -68,667 | -68,034 | 8,037 | -28,247 | -22,805 | -37,561 |
Short-Term Debt Issued | - | 20,000 | 43,500 | 139,700 | 157,800 | 88,700 |
Long-Term Debt Issued | - | 30,000 | - | 44,185 | 770 | - |
Total Debt Issued | 158,000 | 50,000 | 43,500 | 183,885 | 158,570 | 88,700 |
Short-Term Debt Repaid | - | -10,000 | -49,500 | -162,350 | -145,450 | -90,740 |
Long-Term Debt Repaid | - | -30,481 | -15,566 | -677.41 | -3,483 | -6,505 |
Total Debt Repaid | -167,321 | -40,481 | -65,066 | -163,027 | -148,933 | -97,245 |
Net Debt Issued (Repaid) | -9,321 | 9,519 | -21,566 | 20,857 | 9,637 | -8,545 |
Repurchase of Common Stock | - | - | - | - | -6,749 | - |
Dividends Paid | -7,742 | -7,742 | -7,742 | -7,742 | -7,917 | -7,917 |
Other Financing Activities | -0 | -0 | - | -0 | - | - |
Financing Cash Flow | -17,064 | 1,776 | -29,308 | 13,115 | -5,029 | -16,463 |
Miscellaneous Cash Flow Adjustments | 2,857 | 2,857 | - | - | -0 | - |
Net Cash Flow | -41,750 | -12,711 | 16,302 | -1,003 | 2,331 | -7,269 |
Free Cash Flow | 27,530 | 40,383 | 29,421 | 6,049 | 11,189 | 30,824 |
Free Cash Flow Growth | -42.36% | 37.26% | 386.35% | -45.93% | -63.70% | 90.47% |
Free Cash Flow Margin | 11.09% | 18.15% | 14.22% | 3.20% | 6.59% | 16.80% |
Free Cash Flow Per Share | 1777.90 | 2607.96 | 1900.03 | 390.67 | 718.13 | 1946.62 |
Cash Interest Paid | 3,050 | 2,101 | 2,869 | 2,949 | 1,253 | 1,295 |
Cash Income Tax Paid | 10,805 | 5,113 | 6,433 | 6,044 | 9,537 | 4,778 |
Levered Free Cash Flow | 10,427 | 5,915 | 26,784 | 8,717 | 10,273 | 21,798 |
Unlevered Free Cash Flow | 11,715 | 7,203 | 28,467 | 10,649 | 11,073 | 23,429 |
Change in Working Capital | -2,265 | 2,964 | -1,217 | -22,381 | -3,658 | -1,593 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.